PACTR202101800162440招募中3 期
A phase 3, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of a respiratory syncytial virus (RSV) prefusion F subunit vaccine in infants born to women vaccinated during pregnancy
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Pfizer Inc.
- 入组人数
- 6,900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- Female
入选标准
- •Please refer to clintrials.gov or protocol for complete Inclusion/Exclusion criteria. In brief, healthy women >=18 and <=49 years of age who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination with an uncomplicated, singleton pregnancy who are at no increased risk for complications.
排除标准
- •Please refer to clintrials.gov or protocol for complete Inclusion/Exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
16-week efficacy and 2-year safety, tolerability and efficacy of secukinumab in participants with active psoriatic arthritis.MedDRA version: 20.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2014-003849-10-BGovartis Pharma Services AG341
撤回
3 期
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosisdisease of the central nervous system10007951multiple sclerosisNL-OMON30517Clinical Research Assistance25
进行中（未招募）
1 期
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)Subjects at high risk of converting to Multiple SclerosisMedDRA version: 9.0Level: PTClassification code 10028245EUCTR2006-002982-38-SKMerck Serono International, a branch of Laboratoires Serono SA An affiliate of Merck KGaA480
进行中（未招募）
不适用
A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC). - ATTRACT-2Patients with stage IIIb/IV NSCLC of all histologies, who have progressed while on or following a first-line therapy treatment (including bevzcizumab and/or EGFR inhibitors) and are eligible for second-line line chemotherapyMedDRA version: 9.1Level: LLTClassification code 10066490Term: Progression of non small cell lung cancerEUCTR2008-002309-38-GBovartis Pharma Services AG900
进行中（未招募）
不适用
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)EUCTR2006-002982-38-PTMerck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany480